In vivo persistence of adoptively transferred TCR gene-transduced lymphocytes with anti-tumor reactivity in patients with MAGE-A4 expressing esophageal cancer by Hiroaki Ikeda et al.
ORAL PRESENTATION Open Access
In vivo persistence of adoptively transferred TCR
gene-transduced lymphocytes with anti-tumor
reactivity in patients with MAGE-A4 expressing
esophageal cancer
Hiroaki Ikeda1*, Shinichi Kageyama1, Naoko Imai1, Yoshihiro Miyahara1, Mikiya Ishihara1, Naoyuki Katayama2,
Hirofumi Yoshioka3, Daisuke Tomura3, Ikuei Nukaya3, Junichi Mineno3, Kazuto Takesako3, Hiroshi Shiku1
From Society for Immunotherapy of Cancer 28th Annual Meeting
National Harbor, MD, USA. 8-10 November 2013
The application of adoptive immunotherapy with tumor-
specific T cells has been limited because of the short life
span of the transferred T cells unless the host has been
manipulated. Engineering the antigen receptor gene in
patients’ lymphocytes is one promising strategy to create
antigen-specific lymphocytes without senescent pheno-
types. The strategy provides an opportunity to broaden
the types of cancer to be treated. However, this concept
has not been tested in the epithelial cancer patients. We
completed a phase I clinical trial of TCR gene therapy
targeting MAGE-A4 to treat esophageal cancer patients
without lympho-depleting pre-conditioning. The trial
was designed as a cell-dose escalation consisting of
three cohorts, 2×10E8, 1×10E9 and 5×10E9 cells/patient.
The treatment was tolerable with no adverse events
associated with transferred cells. In all ten patients of
the 3 cell-doses, the transferred lymphocytes were
detected in their peripheral blood in a dose-dependent
manner during the first 14 days. In 4 patients, the
infused cells have been persisting more than 5 months
after the transfer. The T cell clones were established
from the transferred lymphocytes that were harvested
more than 100 days after the transfer. These clones sus-
tained the reactivity to the antigen-expressing tumor
cells. Three patients showed SD or long tumor free sta-
tus. These results suggest that this approach may extend
the availability of adoptive T cell therapy for epithelial
cancer patients by providing tumor-reactive and long
surviving lymphocytes reducing the risk of intensive pre-
treatments.
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